Lantheus Holdings (STU:0L8) ROCE %: 33.22% (As of Mar. 2026)


STU:0L8 Lantheus Holdings Inc STU:0L8
87 GF Score
Price €96.50
GF Value €79.89
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lantheus Holdings ROCE %?

Lantheus Holdings STU:0L8 +1.37% 87 ROCE % is 33.22% as of Mar. 2026. GuruFocus rates STU:0L8 with a GF Score™ of 87/100 and a GF Value™ of €79.89 (Modestly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lantheus Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 33.22%.

Lantheus Holdings  (STU:0L8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lantheus Holdings ROCE % Related Terms

Lantheus Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Lantheus Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantheus Holdings ROCE % Chart

Lantheus Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.93 3.77 33.55 28.65 17.37

Lantheus Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.50 23.26 9.97 15.80 33.22
STU:0L8
87GF Score
Lantheus Holdings Inc STU:0L8
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantheus Holdings ROCE % Calculation

Lantheus Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=284.844/( ( (1891.225 - 229.702) + (1902.199 - 284.74) )/ 2 )
=284.844/( (1661.523+1617.459)/ 2 )
=284.844/1639.491
=17.37 %

Lantheus Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=557.992/( ( (1902.199 - 284.74) + (2029.798 - 288.189) )/ 2 )
=557.992/( ( 1617.459 + 1741.609 )/ 2 )
=557.992/1679.534
=33.22 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 33.22% mean?
Lantheus Holdings (STU:0L8) has a ROCE % of 33.22% as of Mar. 2026.
Is Lantheus Holdings' ROCE % too high?
Lantheus Holdings' current ROCE % is 33.22%. The Drug Manufacturers industry median ROCE % is 7.01. Lantheus Holdings' value of 33.22% is 373.9% above this industry median. Overall, Lantheus Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' ROCE % compare to LQDA and HIMS?
Lantheus Holdings' ROCE % of 33.22% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Lantheus Holdings' value of 33.22% is 373.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current ROCE % of 33.22% is 373.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current ROCE % is 33.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Modestly Overvalued. The stock's GF Value™ is €79.89, compared to a current price of €96.50 — trading 20.8% above its estimated fair value. The current ROCE % is 33.22% and 373.9% above the Drug Manufacturers industry median of 7.01. Lantheus Holdings' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current ROCE % is 33.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lantheus Holdings (STU:0L8) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of €96.50 is trading 20.8% above its estimated GF Value™ of €79.89. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for STU:0L8:

  • ROCE %: 33.22%
  • GF Value™: €79.89 vs. price of €96.50 (20.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs
  • Industry Position: 373.9% above the Drug Manufacturers median

No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lantheus Holdings Business Description

Other Exchanges LNTH:USA1LNTH:Italy
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
87GF Score

Get the complete analysis for STU:0L8

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€96.50
Price
€79.89
GF Value